This article is more than 5 years old. Information may no longer be current.

ACC announces late-breaking clinical trials slated for presentation at annual meeting

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American College of Cardiology has announced the line-up of late-breaking clinical trials and featured clinical research at the Annual Scientific Session and Expo, held March 14 to 16 in San Diego.

According to the ACC, the meeting will highlight five late-breaking clinical trial sessions; two featured clinical research sessions; a “Deep Dive” session to address key elements of the late-breaking clinical trials and implications for patients and practice; and much more.

Meeting highlights

Some of the late-breaking clinical trials slated for presentation include:

• PROMISE: A randomized comparison of anatomic vs. functional strategies for diagnostic testing in symptomatic patients with suspected CAD.
• PEGASUS-TIMI 54: A randomized comparison of ticagrelor (Brilinta, AstraZeneca) vs. placebo on a background of aspirin for the prevention of CV events in patients with prior MI.
• OLSER-1 and 2: Two trials designed to assess the impact of evolocumab (Amgen) on CV outcomes.
• REGULATE-PCI: A randomized comparison of the REG1 anticoagulation system vs. bivalirudin (Angiomax, The Medicines Company) in patients undergoing PCI.
• 5-year outcomes of the PARTNER 1 trial, which assessed transcatheter vs. surgical aortic valve replacement.
• 2-year outcomes of the CoreValve US Pivotal High Risk Trial, which compared self-expanding transcatheter and surgical aortic valve replacement in patients with severe aortic stenosis at high surgical risk.
• BEST: A comparison of everolimus-eluting stents and bypass surgery in patients with multivessel CAD.

Other research scheduled for presentation during featured clinical research sessions include an assessment of dual antiplatelet therapy for longer than 1 year among patients with ACS treated with coronary stents; additional data from IMPROVE-IT on the effect of ezetimibe and simvastatin (Vytorin, Merck) vs. simvastatin alone (Zocor, Merck) on CV events after ACS; the AUGMENT-HF trial of the Algisyl-LVR device (LoneStar Heart) with standard medical therapy among patients with advanced HF; and more.

Live coverage

The Healio.com/Cardiology and Cardiology Today staff will provide live coverage from the ACC Annual Scientific Session and Expo, including reports on the clinical trials described above and others presented at the meeting, onsite video interviews with key experts and much more. Visit the website during the meeting and beyond for the latest news from this conference.